Clinical trials
Randomized Clinical Trial clinical trials
Below are recruiting randomized clinical trial clinical trials, each written for real people, not researchers. We’re tracking 523 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07658248Recruiting
Group therapy for breakup distress and relationship issues
This trial tests if psychodrama group therapy can help people who are struggling with feelings from a past breakup or having trouble in their current relationship. It explores a creative, action-based therapy to improve emotional well-being.
Porto, Porto DistrictAges 18 years+ - NCT07107256RecruitingPhase 3
Study of TQC2731 for chronic sinusitis with nasal polyps
This trial tests an injectable drug called TQC2731 for people with chronic sinusitis and nasal polyps that haven't been controlled well enough by standard treatments like steroid sprays or surgery. The goal is to see if it helps reduce nasal congestion, improve sense of smell, and shrink polyps.
Fuyang, AnhuiAges 18–75 - NCT06764953Recruiting
Amnion membrane graft for non-healing leg ulcers
This study tests a special amnion membrane graft to help heal chronic leg ulcers that haven't improved with standard care. The graft is placed on the wound to support healing, and results are compared with standard treatment alone.
Roanoke, VirginiaAges 18 years+ - NCT07186426RecruitingPhase 3
Testing HSK21542 for pain after hip replacement surgery
This trial tests a new pain medicine called HSK21542 for people who have hip replacement surgery under general anesthesia. It aims to see if the drug can safely reduce moderate to severe pain after surgery.
Beijing, Beijing MunicipalityAges 18–74 - NCT07510412Recruiting
NuShield plus standard care for venous leg ulcers
This trial tests a new wound covering called NuShield, used with standard care, to help heal leg ulcers caused by poor vein circulation. It may be an option if your ulcer hasn't healed after standard treatment.
Pickerington, OhioAges 18 years+ - NCT06087536RecruitingPhase 2
Trial of OMN6 for hospital-acquired Acinetobacter pneumonia
This trial tests a new antibiotic called OMN6 for people with a serious lung infection (pneumonia) caught in the hospital or from a breathing machine, caused by a hard-to-treat bacteria (Acinetobacter). The goal is to see if OMN6 is safe and how the body processes it.
AshdodAges 18–99 - NCT07533786RecruitingPhase 2
New Pain Medicine After Abdominal Surgery
This study tests a new medication called HSK55718 to treat pain after abdominal surgery. If you're having moderate to severe pain within 4 hours of surgery, this trial may help you get relief and contribute to finding better pain treatments.
Changsha, HunanAges 18 years+ - NCT05824728RecruitingPhase 2
Levetiracetam for Parkinson’s psychosis with study partner support
This Phase 2 study tests whether AGB101 (levetiracetam) can reduce hallucinations, delusions, or related symptoms in people with Parkinson’s disease psychosis, while checking safety. You and a study partner will help with dosing and regular check-ins, including MRI scans.
Baltimore, MarylandAges 40–85 - NCT07591298RecruitingPhase 2
SYH2070 injection for homozygous familial high cholesterol
This study tests a new injectable medication (SYH2070) designed to lower cholesterol in people with homozygous familial hypercholesterolemia—a genetic condition that causes extremely high cholesterol levels despite treatment. The goal is to see if this drug safely reduces cholesterol better than current options.
Changsha, HunanAges 18 years+ - NCT06959108RecruitingPhase 2
Comparing two treatments for head and neck cancer before chemoradiation
This trial tests two different drug combos—one using an EGFR-targeted therapy alone, the other adding an immunotherapy—before standard chemoradiation for locally advanced head and neck cancer. The goal is to see which approach works better without prior treatment.
VillejuifAges 18–75 - NCT05568212RecruitingPhase 2
Trial of immune combination versus standard care for NSCLC relapse
This Phase 2 trial studies an immune-based drug combination compared with standard care for lung cancer that has come back after chemoradiation and durvalumab. It aims to improve control of the cancer after durvalumab is no longer working.
Roma, RMAges 18 years+ - NCT06962410Recruiting
Hybrid Closed-Loop for Diabetes After Kidney Transplant
This trial tests a hybrid closed-loop system (an advanced insulin pump that automatically adjusts insulin) for people with diabetes who have had a kidney transplant. It may help improve blood sugar control and reduce the burden of managing diabetes after transplant.
Taiyuan, ShanxiAges 18–70 - NCT06423612Recruiting
HIV monitoring with a urine test to improve viral suppression
This trial tests whether a simple urine test can help people living with HIV who have not yet achieved viral suppression. The test is done right at the clinic to quickly check if their HIV medication is being taken correctly, so their doctor can offer extra support.
East LondonAges 18 years+ - NCT06828887RecruitingPhase 2
Testing LV232 capsules for major depression
This trial tests a new medicine called LV232 for people with moderate to severe depression. Researchers want to find the best dose and check if it works safely.
ShanghaiAges 18–65 - NCT06835725RecruitingPhase 2
Comparing two prostate radiation schedules for intermediate risk
This trial compares giving radiation in 2 treatments versus 5 treatments for prostate cancer that hasn't spread. It's for men with low or intermediate risk prostate cancer who are healthy enough to undergo a short course of targeted radiation.
Surrey, British ColumbiaAges 18 years+ - NCT07018245RecruitingPhase 2
TJ0113 Capsule for depression: a phase 2 study
This trial tests an investigational medication called TJ0113 for people with moderate to severe depression. It aims to see if the drug can safely improve depression symptoms when other treatments are stopped during the study.
Hangzhou, ZhejiangAges 18–65 - NCT05812807RecruitingPhase 3
Pembrolizumab versus monitoring after triple-negative breast cancer response
This trial checks whether giving pembrolizumab (an immunotherapy) after surgery helps people with triple-negative breast cancer reduce the chance of the cancer coming back, compared with close monitoring only. It’s for patients who had no remaining invasive cancer after neoadjuvant chemotherapy plus pembrolizumab.
Birmingham, AlabamaAges 18 years+ - NCT06724718Recruiting
Using a smartwatch to detect atrial fibrillation after chest surgery
This trial tests whether a smartwatch can detect atrial fibrillation in people who have had major chest surgery (like lung removal) within the last 48 hours. If successful, this could help catch heart rhythm problems early without extra hospital equipment.
AmiensAges 18 years+ - NCT07269717RecruitingPhase 2
Testing HRS-1893 for heart failure with preserved ejection fraction
This trial tests a new drug called HRS-1893 for people with heart failure with preserved ejection fraction (HFpEF). It aims to see if the drug can improve symptoms and quality of life.
Shanghai, Shanghai MunicipalityAges 40 years+ - NCT07377045RecruitingPhase 1
New combo for advanced pancreatic cancer
This trial tests a new drug (OMTX705) combined with standard chemotherapy (gemcitabine/nab-paclitaxel) and an immunotherapy (tislelizumab) for people with advanced pancreatic cancer. It may be an option if you have had little or no prior chemotherapy.
Boston, MassachusettsAges 18 years+ - NCT06993155RecruitingPhase 2
Leflutrozole for low testosterone and low sperm count
This trial tests a new drug called Leflutrozole to see if it can improve testicular function in men with low testosterone and low sperm count. The goal is to help increase natural hormone levels and sperm production.
North Hollywood, CaliforniaAges 18–49 - NCT05994690RecruitingPhase 3
Newly diagnosed pediatric AML trial with extra treatment options
This trial studies different treatment plans for children and teens newly diagnosed with AML (a type of blood cancer). Depending on the child's tumor markers and risk group, they may be offered an extra drug (quizartinib) or a targeted antibody (Mylotarg) to see if it improves outcomes.
Utrecht, UtrechtAges 1 day–18 years - NCT06521047Recruiting
Long-term follow-up for EXCELLENT trial participants
This study looks at the long-term health of people who took part in the EXCELLENT trial. If you finished that trial within the last 10 years, you may be able to join this study to help researchers understand how participants are doing over time.
Mulhouse, FranceAges 18 years+ - NCT07225881Recruiting
Eatwell diet study for cancer survivors and their families
This study tests a program to help households eat better based on cancer prevention guidelines. You and an adult you live with will join together to see if the program improves your diet.
Philadelphia, PennsylvaniaAges 18 years+
Hear when a new Randomized Clinical Trial trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for randomized clinical trial?
- Yes. Clin2 currently lists 523 recruiting randomized clinical trial studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a randomized clinical trial trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a randomized clinical trial trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.